SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-059784
Filing Date
2022-03-01
Accepted
2022-03-01 07:07:04
Documents
14
Period of Report
2022-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d65091d8k.htm   iXBRL 8-K 25126
2 EX-99.1 d65091dex991.htm EX-99.1 88302
6 GRAPHIC g65091dsp01a.jpg GRAPHIC 22330
  Complete submission text file 0001193125-22-059784.txt   276305

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20220301.xsd EX-101.SCH 2874
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20220301_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20220301_pre.xml EX-101.PRE 10824
8 EXTRACTED XBRL INSTANCE DOCUMENT d65091d8k_htm.xml XML 3240
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 22693910
SIC: 2834 Pharmaceutical Preparations